Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced the immediate appointment of Ashley Kline as Chief Commercial Officer. With a proven history of launching therapies for rare diseases, …
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has released its financial results for the first quarter of 2025, along with key updates from its clinical development programs for QTORIN™ …
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will release its first quarter 2025 financial results on Thursday, May 15, 2025.
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will mark a significant corporate milestone by ringing the opening bell at the Nasdaq Stock Market on Monday, May 12, 2025, in …
Palvella Therapeutics to Ring Nasdaq Opening Bell Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that an abstract presenting groundbreaking data on the prevalence and annual incidence of lymphatic malformations (LMs) in the U.S. has been …
Palvella Therapeutics to Present Key Findings on Lymphatic Malformations at Dermatology Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORIN™ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare …
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations (microcystic LMs) at the 15th World …
Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that its Founder and Chief Executive Officer, Wes Kaupinen, will take part in a fireside chat at the Jones Healthcare …
Palvella CEO to Present at Healthcare Innovation Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will take center stage at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina, with a late-breaking oral presentation on …
Palvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology Congress Read More